



ASX release

17 June 2015

Successful Share Placement and Rights Issue

AtCor Medical (ASX:ACG) marketer of the SphygmoCor® system, which noninvasively measures central aortic blood pressures and arterial stiffness, announced today it has successfully raised \$2.2 million from sophisticated and institutional investors at \$0.18 per share. The company is now offering all shareholders an opportunity to participate in a fully underwritten 1 for 10 non-renounceable rights issue at \$0.18 to raise a further \$3.2 million.

Securing a CPT1 code covering the SphygmoCor test has been a seminal event for AtCor. The capital raise will help to ensure the company is fully prepared for 1 January 2016 when the code takes effect, facilitating investment in additional sales and support personnel, consulting services and other activities to ensure that the organisation is ready for launch. The Board of AtCor Medical believes it is prudent to conduct the capital raise at this time to ensure AtCor can take full advantage of the market opportunity.

AtCor Medical CEO, Duncan Ross, said: "We are pleased by the support from institutional investors for this equity issue, and delighted to offer retail shareholders the opportunity to participate via a rights issue. These new funds will allow AtCor to pursue the reimbursement opportunity that is now available in the USA following the CPT1 code being awarded in March this year."

All shareholders are encouraged to take part in the Rights Issue. The Rights Issue is fully underwritten by Taylor Collison. Rights Issue booklets will be mailed to shareholders on 1 July 2015.

Offer Summary

Share Placement (completed)	<ul style="list-style-type: none">• To raise up to \$2.2m• Issue up to 12,400,000 new fully paid ordinary shares• Issue Price of \$0.18• Placement participants eligible for entitlement offer
1 for 10 non-renounceable rights issue	<ul style="list-style-type: none">• To raise up to \$3.2m• Issue up to 17,793,393 new shares• Issue Price of \$0.18 (same as placement price)
Capital structure effects	<ul style="list-style-type: none">• Current issued capital: 169,979,646 (84.73%)• Placement: 12,400,000 (6.18%)• Entitlement Issue: 17,793,393 (9.09%)• Indicative issued capital: (up to) 200,638,511 (100%)• Indicative market capitalisation at 18c: \$36.0m
Discount offered	<ul style="list-style-type: none">• 20% to 15 day VWAP of \$0.218• 16% to 10 day VWAP of \$0.208• 10% to 5 day VWAP of \$0.198• 14% to last trade of \$0.205

Rights Issue Details

Who may participate	All Australian and New Zealand shareholders
Offer	1 share for every 10 shares held at the record date
Offer price	\$0.18
Ex date	Friday, 26 June 2015
Record date	Tuesday, 30 June 2015
Offer opens	Monday, 6 July 2015
Offer closes	Thursday, 16 July 2015
Issue date	Thursday, 23 July 2015
New shares commence trading on ASX	Friday, 24 July 2015

About AtCor Medical

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central aortic blood pressure non-invasively. The company's SphygmoCor[®] system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 3,800 SphygmoCor[®] systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in over 900 peer-reviewed studies published in leading medical journals and thousands of citations. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at www.atcormedical.com.

For further information, please contact

Duncan Ross – AtCor Medical CEO
+1 (630) 228 8873

Peter Manley – AtCor Medical CFO
+61 (2) 8815 8811

Media enquiries to:

Ashley Rambukwella – Financial &
Corporate Relations
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or
a.rambukwella@fcr.com.au